Company news

Fate Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy

July 8, 2020

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 10, 2020

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

June 8, 2020

Fate Therapeutics Announces Proposed Public Offering of Common Stock

June 7, 2020

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

May 19, 2020

Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress

May 10, 2020

Fate Therapeutics Announces Changes to its Board of Directors

May 4, 2020

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results

May 3, 2020

Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting

April 27, 2020

Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies

April 1, 2020

Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

April 1, 2020

Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook

March 1, 2020

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

January 12, 2020

Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

December 9, 2019

Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

December 7, 2019

Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

December 6, 2019

Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

November 26, 2019

Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

November 13, 2019

Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting

November 5, 2019

Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

November 4, 2019

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results

October 28, 2019

Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

September 29, 2019

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

September 17, 2019

Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development

April 17, 2019

Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment

April 1, 2019

Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting

March 31, 2019

← Newer news releases

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 19 decks. Every deck is listed under its year.